Community protesting demolition of Eastern High School
LANSING, Mich. (WLNS) – A group advocating for parts of Eastern High School to be saved gathered at Lansing City Hall to voice their concerns.
'The Eastern grads are many in this town,' said Linda Peckham, a member of the Coalition to Preserve Eastern High School and Promote Mental Health. 'There are hundreds and hundreds and hundreds who vote and they are very attached to the building for emotional reasons [and] personal reasons because it's a gorgeous building.'
Eastern High School is nearly a century old, and some people in the Greater Lansing area feel connected to the space. For some, it even runs in the family.
'I have four younger sisters, and we all graduated from Eastern, and even my mother graduated from Eastern,' said Faye Norris, who is also part of the coalition.
The group says they are interested in preserving the West Wing and the auditorium.
'The building is quite dilapidated,' said Margaret Dimond, regional president of U-M Health.
Unfortunately, the building hasn't held up the same way many Quakers' memories have.
'The auditorium has water intrusion, mold, black mold, and the asbestos is everywhere…Anyone going through there should have an N95 mask on,' Dimond continued.
She says that given its current state, saving the space simply isn't an option.
'I don't think they understand that a lot of the water intrusion is behind the walls,' said Dimond.
Dimond says plans have been made to keep and highlight artifacts that could be preserved on the new property.
'That includes the beautiful arches and includes the cupula…Things that are historic, we can put around the park,' she said.
The coalition is hoping for the city to do a preservation analysis.
'We're trying to get the mayor to pause the demolition long enough to have that analysis made,' said Peckham.
The group also says they understand and support the need for a new mental health facility
'[They] say we're not interested in mental health, we're only interested in preserving an old building… No. Not true,' said Peckham.
Thursday morning, Lansing Mayor Andy Schor gave 6 News a statement saying if Sparrow meets all the requirements, the city has to issue the permit to allow for demolition.
The city added that if it were to intervene in the project, a lawsuit would likely follow—costing taxpayers money and still resulting in the demolition of Eastern High School.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Vivani Medical to Present at the 2025 BIO International Convention
ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the 'Company' or 'Vivani'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention, taking place from June 16-19, 2025 in Boston, Massachusetts. Details around Dr. Mendelsohn's presentation are as follows: Date: Wednesday, June 18, 2025 Time: 9:00 am, Eastern Time Location: Boston Convention & Exhibition Center, Room 153A Dr. Mendelsohn will highlight Vivani's innovative, miniature drug implants, powered by its proprietary NanoPortal™ drug implant technology. These ultra long-acting implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. Vivani's lead program, NPM-115, is a six-month GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Results from LIBERATE-1™, the first human clinical trial of NPM-115, are expected later this year. More information about the BIO International Convention can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani's lead programs, NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), are miniature, subdermal GLP-1 implants under development for chronic weight management in obese or overweight patients designed for once- or twice-yearly administration. Vivani's emerging pipeline also includes NPM-119, which refers to the Company's six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a semaglutide implant for the treatment of type 2 diabetes is also under consideration. These NanoPortal implants are designed to provide patients with the opportunity to experience the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of oral and injectable medications. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature, ultra long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers. For more information, please visit: Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'potential,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 trial and reporting of trial results, Vivani's emerging development plans for Vivani's products, including NPM-115, NPM-139, NPM-119, and Vivani's technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities; risks related to the initiation, enrollment and conduct of Vivani's planned clinical trials and the results therefrom; Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business; market conditions and the ability of Cortigent to complete its intended spin-off from the Company. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact:Donald DwyerChief Business Officerinfo@ 506-8462 Investor Relations Contact:Jami TaylorInvestor Relations Advisorinvestors@ 506-8462 Media Contact:Sean LeousICR 866-4012Sign in to access your portfolio
Miami Herald
21 hours ago
- Miami Herald
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / June 9, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern tomorrow, Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. Participation Instructions for Jaguar Health's Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series When: Tuesday, June 10, 2025 from 9:00 - 10:00 AM Eastern Where: Online (Click Here). The fireside chat will also be available for replay following the event. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners' spring 2025 Spotlight Series, Jaguar's expectation that the currently estimated US metastatic breast cancer population may qualify as an orphan population, and Jaguar's expectation that it will promptly pursue authorization to initiate an expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer patients. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Source: Jaguar Health, Inc. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Newsweek
a day ago
- Newsweek
Alert Urging People to Check Themselves for Coughs Remains in One State
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Officials in Maine are urging people to monitor themselves for symptoms such as coughing as poor air quality persists across parts of the state on Monday from Canadian wildfires. National Weather Service (NWS) meteorologist Greg Cornwell, who works at the Gray, Maine, office, told Newsweek that the smoke might dissipate from Maine on Tuesday but looks like it will return by Tuesday night. Why It Matters Experts and public health authorities have pointed to the increased frequency and distribution of air quality alerts as evidence of persistent and growing challenges posed by air pollution in the United States. Nearly half of Americans currently live in areas receiving failing grades for particulate or ozone pollution, according to the American Lung Association's (ALA) "State of the Air" report. Over the past few weeks, wildfire smoke from Canada has descended into the U.S. and further worsened the air quality in some states. Among them, Maine has been on high alert, with residents advised to monitor themselves for symptoms if they are exposed to the polluted air. What to Know Smoke from Canadian wildfires significantly degraded air quality across large portions of the U.S. during the past week, leading to the issuance of air quality alerts in several states. These alerts specifically advised residents to monitor themselves for symptoms such as coughing, as exposure to wildfire smoke can trigger respiratory difficulties and, in some cases, increased risks for heart attacks and strokes, as Dr. Scott Budinger, chief of pulmonary and critical care at Northwestern University, previously told Newsweek. The most affected regions included the Upper Midwest, Great Lakes, and parts of the Northeast. At the height of the alerts, states such as Maine, Michigan, and Wisconsin were advised to be especially vigilant, with public health authorities urging individuals who develop symptoms like coughing, throat irritation, or shortness of breath to limit outdoor activity. The alert persists in Maine on Monday, with officials from the Maine Department of Environmental Protection (DEP) highlighting risks for particularly sensitive populations, including children, the elderly, and those with pre-existing respiratory or heart conditions. The most recently issued air quality alert relayed by the NWS is in place for the cities of Biddeford, Saco, Old Orchard Beach, Kittery, Portland, Cape Elizabeth, South Portland, Westbrook, Yarmouth, Brunswick, Arrowsic, Bath, Phippsburg, Bowdoinham, Topsham, and Bowdoin. The affected areas expect to see PM2.5 levels—fine particulate pollution commonly associated with wildfire smoke—rising to the 'Unhealthy for Sensitive Groups' range on the Air Quality Index on Monday. As of 10:30 a.m. Eastern time, air monitoring stations across Maine reported "Moderate" air quality. Health officials across multiple states instructed residents to closely observe their respiratory health during these periods of poor air quality. Recommendations included avoiding strenuous outdoor activity, keeping windows closed overnight, and using home air purifiers with high-efficiency filters. Alerts pointed to a particular danger for those with asthma or cardiovascular disease, with guidance for high-risk individuals to keep medications on hand and seek medical advice if symptoms persist or intensify. If someone experiences coughing as a symptom, Dr. Panagis Galiatsatos, a volunteer medical spokesperson with the American Lung Association (ALA), told Newsweek that they should see their doctor if the cough is accompanied by breathlessness or lasts for more than seven days. What People Are Saying National Weather Service meteorologist Greg Cornwell told Newsweek: "Tuesday during day will be more clear of smoke. By evening, that [upper-level low pressure system] will be pushing more smoke into the region heading into Tuesday night. It won't be quite as potent toward surface, which is good news for folks sensitive to that." Dr. Panagis Galiatsatos previously told Newsweek: "Your cough itself doesn't need emergent medical attention. However, if you're also experiencing breathlessness, talk to your doctor or seek more urgent care." NWS air quality alert for Maine: "The Maine Department of Environmental Protection recommends that individuals consider limiting strenuous outdoor physical activity to reduce the risk of adverse health effects. People who may be especially sensitive to the effects of elevated levels of pollutants include the very young, the elderly, those with pre-existing respiratory problems such as asthma, those with heart disease and anyone who is working hard outdoors. It is okay to be active outdoors. But if you experience symptoms such as shortness of breath, coughing, throat irritation or an uncomfortable sensation in your chest please consider limiting the intensity and duration of your outdoor activities." What Happens Next? The most recent air quality alert in Maine is expected to expire by midnight on Monday. However, it is possible more alerts will be issued depending on how weather trends affect the direction of the wildfire smoke this week.
